BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $133
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $117 to $133.
BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $117 to $133.